Original Publication Date: 1 January, 2015
Publication / Source: CNS Oncology
Authors: Anna S Berghoff, Johannes A Hainfellner, Christine Marosi & Matthias Preusser
MGMT promoter methylation status is a strong and independent prognostic factor in patients with newly diagnosed glioblastoma and a clinically relevant predictive marker in the subpopulation of elderly glioblastoma patients. However, there is still lack of consensus on the optimal assay for reliable MGMT promoter methylation testing and a variety of tests are being used in different laboratories.